Technical personnel before

France developed a molecular diagnostic testing technology, which can detect human papillomavirus to prevent cervical cancer.

women in developing countries, cervical cancer and cause of death, but also the world's women face the second most common cancer. Cervical cancer worldwide each year due to the number of deaths reached 25 million people. 99.7% of cervical cancer is caused by human papillomavirus infection. Research shows in the world caused by the human papilloma virus cervical cancer, 70% of the virus gene 16 and 18 caused.

human papillomavirus infection in most cases are temporary. However, in 20% of the women, the sustainability of this infection, resulting in damage to the cervix. 1% to 10% of the injury can develop into cervical cancer. Therefore, we must clear at an early stage which women face high risks, and disease of the body may develop into cervical cancer.

human papillomavirus detection of molecular diagnostic techniques can be used to detect early cancer lesion with possible cervical injury. These methods and cytology check (Papanicolaou cervical smear) used to help determine which women with abnormal cytology results (ASCUS, that is, the meaning is not clear pneumonia type squamous cell), and then of these women cervical examination, biopsy Laboratory , and for treatment.

now used by most elements of human papillomavirus test can detect the virus deoxy - ribonucleic acid (DNA), thereby demonstrating the cervical cells which have the virus. However, only the existence of positive detection of human papillomavirus infection, and this infection may be temporary, there may be ongoing. Test results did not indicate whether the cancer-causing virus, that is to say, doctor and can not be based on evaluation of HIV test results it has the potential to lead to the possibility of cancer.

scientists can now confirm that cancer-causing virus protein E6 and E7 expression is sustained in the viral genes of host cells and cervical gene generated combined. This abnormal expression of cell cycle will lead to a change, eventually leading to large volume cell proliferation, and thus a result of the process of cervical carcinogenesis. Therefore, this expression is the early signs of cervical cancer.

more than the literature indicates that, for the detection of cytologic diagnosis of ASCUS and LSIL (low-grade squamous intraepithelial lesion) of the women, if the messenger ribonucleic acid (mRNA) appears E6/E7 cancer detection gene expression, to a large extent will appear in precancerous lesions. MRNA detection in the diagnosis of this more targeted, DNA-based detection, compared with higher medical value. These test results help to more accurately determine the patients for the need for further endoscopic examination of uterus, and thus to minimize unnecessary damage check - and physiological cervical biopsy sections - the number of.

BioMerieux France introduced this NucliSENS EasyQ HPV reagents is based on the concept of this innovative detection methods, can lead to cervical cancer in the world of the five kinds of the most common human papillomavirus (HPV 16, HPV 18, HPV 31, HPV 33 and HPV 45) were directly detected by high-risk gene expression in cancer. Using this specific method of detection, doctors would have a high medical value of the detection technology, which greatly improved the treatment of patients.

It is, E6/E7 mRNA detection of clinical value in the medical profession is widely recognized gradually, Denmark has recently been in the national cervical cancer screening guidelines which included the use of this technology.